Nicholas Ede

Nicholas Ede has a diverse work experience spanning different companies and roles. Nicholas served as the Chief Technology Officer at Imugene Limited, where they were responsible for developing immunotherapies for cancer patients. Prior to that, they held the same role at Rhinomed Limited Australia, where they oversaw the development of medical devices. Nicholas also served as the CEO and R&D Director at Adistem Ltd., and as the CEO at Mimotopes, where they managed the business, research and development, and new product development. Additionally, they worked as the Chief Operating Officer at EQiTX, where they managed a preclinical development program. Lastly, they were the Head of Discovery Products and Combinatorial Chemistry at Chiron Corporation, where they led a team involved in research, development, and commercialization.

Nicholas Ede holds an extensive education history. Nicholas obtained their BSci(Hons)PhD in Bioorganic Chemistry from Monash University, where they studied from 1984 to 1991. Following this, they pursued further research, specializing in peptide-oligonucleotide conjugates, as a Research Fellow at the Howard Florey Institute at the University of Melbourne from 1991 to 1994. Nicholas then continued their research work as a Research Fellow in CRC Vaccine Technology, focusing on peptide vaccines, at the University of Melbourne from 1994 to 1995. Additionally, they attended the Melbourne Business School in 2009 to 2010, where they obtained a Graduate Certificate in Innovation.